Furthermore, the addition of the HDAC inhibitor panobinostat significantly contributes to better survival of patients with relapsed multiple myeloma who have a treatment regimen combining the proteasome inhibitor bortezomib and dexamethasone.113. Here, HDAC9 is linked to plasma cell myeloma.